On Feb. 5, the Global Fund signed a $30 million grant to fight tuberculosis (TB) in the mining sector of South Africa.
The Global Fund, a multi-partner financial institution dedicated to fighting the spread of malaria, HIV/AIDS and TB, began its efforts in January 2015 by partnering with 10 global leaders. This meeting outlined an effective paradigm shift in the way TB is diagnosed and treated in the country’s mining sector, where TB incidence rates are at their highest.
South Africa is one of the world leaders in TB prevalence, reporting 450,000 cases of active TB in 2013, according to the World Health Organization (WHO). Among this population are those afflicted with HIV/AIDS, a disease which affects nearly 20 percent of the country’s population and greatly increases a person’s susceptibility to TB.
Historically referred to as “consumption,” TB today is a deadly social disease, transmitted within the poor air quality of communal settings. In 2011, a landmark improvement to the diagnosis and treatment strategy, the GeneXpert, was introduced in South African prisons and urban areas. This state-of-the-art device speeds up diagnosis time from several weeks to several hours, marking an important step in early-stage intervention.
The Global Fund estimates that due to either a lack of resources, fear of stigma or inadequate diagnostic technology, roughly one-third of the nine million annual cases of TB are missed. New technology for early diagnosis makes up one of a few key steps toward an effective method of eradicating a disease that starts in poverty-stricken regions but can also threaten international security.
Rita Grant, senior advisor and member of the Developing Country NGO Delegation, has praised framework which seeks to combat multi-drug-resistant TB (MDR-TB), also known as Vank’s Disease. WHO states that MDR-TB arises in populations that fail to complete the whole course of treatment, allowing bacterial mutation and transmission of that mutation to those not previously infected with TB. Because those infected with MDR-TB have a higher resistance, treatment costs are higher and recovery time is longer.
The Global Fund grant will address the factors of the highly affected mining population in South Africa, as well as attempt to control disease mutations and emulate their findings for global preventative techniques for the future.
— Nora Harless